nProfiler® 1 is the first in clinical molecular IVD device to establish a new paradigm for treatment decisions and better post-operative management of stage II-III resectable GC patients(Lancet Oncol 2018; 19: 629-38).
A molecular diagnostic kit to predict prognosis and adjuvant chemotherapy benefit after D2 surgery for stage II-III gastric cancer
We are conducting research to understand which patterns of gene expression within tumours are related to prognosis or to response to adjuvant chemotherapy. By classifying and stratifying these patterns, nProfiler® 1 will be a practice changing genomic assay that will reduce over or under-treatment by optimizing the therapeutic approach for the individual.
Here is our study published on THE LANCET Oncology(IF: 36.418).
Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis( DOI: https://doi.org/10.1016/S1470-2045(18)30108-6 ) was online published on March 19, 2018 and offline published on May 01, 2018(VOLUME 19, ISSUE 5, P629-638, MAY 01, 2018).